HUS

Hôpitaux Universitaires de Strasbourg

corporate_fareorganization

Web page: http://www.chru-strasbourg.fr/

Country: France

ROR: https://ror.org/04bckew43

ISNI: 000000012177138X

HUS

- Funding / Projects
  (38)

38 Projects, page 1 of 8

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant
assignment_turned_inProjectPartners:HUS, Groupe Hospitalier Pitié Salpétrière, HUG, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Poitiers +10 partners
HUS,
Groupe Hospitalier Pitié Salpétrière,
HUG,
Hôpital Claude Huriez,
Centre Hospitalier Universitaire de Poitiers,
Centre Hospitalier Universitaire de Toulouse,
Centre Hospitalier Universitaire de Limoges,
Institut Paoli-Calmettes- (IPC),
CHRU MTP,
Hôpital Necker- Enfants malades,
HCL,
Institut de cancérologie Lucien Neuwirth,
CHU Nantes - Hôtel Dieu,
CHU,
Groupe Hospitalier Henri Mondor - Albert Chenevier
Funder: Institut National du Cancer Project Code: INCa-DGOS-11089
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Randomized phase III study of gemcitabine and cisplatin (GC) versus high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder
assignment_turned_inProjectPartners:Centre François Baclesse, Centre Léon Bérard, Institut Bergonié, Hôpital Saint-Louis, Institut Curie +6 partners
Centre François Baclesse,
Centre Léon Bérard,
Institut Bergonié,
Hôpital Saint-Louis,
Institut Curie,
Centre Hospitalier Universitaire de Rouen,
HUS,
Institut de cancérologie Lucien Neuwirth,
Institut Paoli-Calmettes- (IPC),
Institut Claudius Regaud,
Institut Gustave Roussy
Funder: Institut National du Cancer Project Code: INCa-DGOS-3712
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Expansion of invariant NKT cells for a cell immunotherapeutic approach allowing the control of graft versus host-disease and preserving the graft versus leukemia effect after allogeneic hematopoietic stem cell transplantation
assignment_turned_inProjectUntil 2021Partners:HUS, Centre Hospitalier Universitaire de La Réunion, Groupe Hospitalier Pitié Salpétrière, Hôpital Saint-Louis, Hôpital Marin +4 partners
HUS,
Centre Hospitalier Universitaire de La Réunion,
Groupe Hospitalier Pitié Salpétrière,
Hôpital Saint-Louis,
Hôpital Marin,
CHU,
Hôpital Necker- Enfants malades,
CNRS UMR 7365 IMoPA,
UMR CNRS 7274
Funder: Institut National du Cancer Project Code: INCa-DGOS-12035
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
TC-NER (Transcription stress Counteracted by Nutritional interventions of Exceptional importance for rare DNA Repair disorders)
assignment_turned_inProjectFrom 2021Partners:False, Koc School of Medicine, HUS, Princess Máxima Center, University of Cologne +1 partners
False,
Koc School of Medicine,
HUS,
Princess Máxima Center,
University of Cologne,
Istituto Firc di Oncologia Molecolare
Funder: French National Research Agency (ANR) Project Code: ANR-20-RAR4-0010
Funder Contribution: 225,000 EUR
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Somatic and constitutional new generation sequencing platform of the Strasbourg Institut Régional du Cancer of Alsace (IRECAL)
assignment_turned_inProject2014 - 2015Partners:Centre Paul Strauss, Hôpital Hautepierre (CHRU), GIE - Centre Européen de Recherche en Biologie et en Médecine, HUS
Centre Paul Strauss,
Hôpital Hautepierre (CHRU),
GIE - Centre Européen de Recherche en Biologie et en Médecine,
HUS
Funder: Institut National du Cancer Project Code: INCa-7567
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

HUS

HUS

Funder

38 Projects, page 1 of 8

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

Randomized phase III study of gemcitabine and cisplatin (GC) versus high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder

Expansion of invariant NKT cells for a cell immunotherapeutic approach allowing the control of graft versus host-disease and preserving the graft versus leukemia effect after allogeneic hematopoietic stem cell transplantation

TC-NER (Transcription stress Counteracted by Nutritional interventions of Exceptional importance for rare DNA Repair disorders)

Somatic and constitutional new generation sequencing platform of the Strasbourg Institut Régional du Cancer of Alsace (IRECAL)

Loading